May 26, 2025 – CEO Sofia Heigis recently presented Oncopeptides at BioStock Global Forum 2025. The presentation was followed by a Q&A session.
May 20, 2025 – Oncopeptides has enrolled the first patient in its new real-world evidence study of Pepaxti in Spain. The LAGOON study will provide new insights into how the medicine performs in clinical practice.
Released May 15, 2025
CEO Sofia Heigis
David Augustsson
Director Corporate Affairs
david.augustsson@oncopeptides.com
+46 762 29 38 68
Oncopeptides AB Interim Report Q2 2025 will be published August 21, 2025
April 16, 2025
The shareholders in Oncopeptides AB are hereby given notice to attend the Annual General Meeting to be held at Tändstickspalatset, Västra Trädgårdsgatan 15, Stockholm, Sweden on Thursday 22 May 2025 at 10.00 a.m.
Read more
March 13, 2025
In the latest episode of Oncopeptalks, David and Sofia discuss the recent news of a first Pepaxti order in Italy and some of the questions following the Q4 report.
Read moreMay 20, 2025
Oncopeptides AB today announces that the first patient has been enrolled in its new real-world evidence study, evaluating the use of Pepaxti in routine clinical settings across Spain.
Read moreApril 16, 2025
Oncopeptides announces the publication of new real-world data that further support the effectiveness and tolerability of melflufen, branded in Europe as Pepaxti, in patients with relapsed, refractory multiple myeloma (RRMM).
Read moreApril 1, 2025
Oncopeptides today announces the U.S. Food and Drug Administration (FDA) has lifted the clinical hold previously placed on Oncopeptides’ next-gen drug OPD5.
Read more
May 16, 2025
Oncopeptides CEO Sofia Heigis was recently interviewed by Richard Ramanius, equity analyst at Redeye, on the topic of the 2025 Q1 report.
Read morePress release - May 22, 2025
Released April 28, 2025
CEO Sofia Heigis
David Augustsson
Director Corporate Affairs
david.augustsson@oncopeptides.com
+46 762 29 38 68
Oncopeptides AB Interim Report Q1 2025 will be published May 15, 2025
2025-07-22 - 2025-08-20
Other
2025-08-21
Report
2025-10-06 - 2025-11-04
Other
”Oncopeptides brings hope to patients through passionate people, innovative science and transformative medicines”
We are a science driven, entrepreneurial company, committed to bringing innovation to patients with an unmet medical need, and improving their lives.
Oncopeptides was formed in 2000 to develop anti-cancer drugs based on research by some of Sweden’s leading cancer researchers and cancer research institutions.
